drugset / Trial / NCT04040634

Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)

NCT04040634

RandomizedParallel-groupSingle-blindTreatment

Summary

High blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly prevalent condition, and it is usually associated with diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events including cardiovascular death, acute myocardial infarction, stroke, unstable angina and heart failure. In addition, high BP is also related to cognitive decline. The OPTIMAL-DIABETES trial consists of a two-arm, multicenter, randomized clinical trial designed to test whether a lower systolic blood pressure (SBP) target will reduce the occurrence of major cardiovascular events in diabetic patients compared to the standard SBP target.

Timeline

Start
2019-08-08
Primary completion
2026-05-31
Completion
2026-05-31

Drugs

EvaluationDrugModalityDoseRoute
Background Amlodipine Other / unclassified
Background Indapamide Small molecule
Background perindopril arginine Unknown